The Rheumatology Podcast

Dr Marwan Bukhari asks Dr Neil Basu (Glasgow, UK) about his recent paper. Using data from the BSRBR-AS, the study aimed to quantify and predict the effect of anti-TNF therapy on axSpA-related fatigue. This paper is the Editor’s Choice for November.

Dr Richard Conway (Dublin, Ireland) and Dr Elena Nikiphorou (London, UK) interview Dr Carlos Fernández-Díaz (Santander, Spain) about his recent paper, which examines the efficacy of abatacept in interstitial lung disease associated with rheumatoid arthritis. Their discussion includes the study’s key learning points, how this research may influence clinical practice, and future research plans.

Dr Richard Conway (Dublin, Ireland) and Dr Elena Nikiphorou (London, UK) interview Dr Carlos Fernández-Díaz (Santander, Spain) about his recent paper, which examines the efficacy of abatacept in interstitial lung disease associated with rheumatoid arthritis. Their discussion includes the study’s key learning points, how this research may influence clinical practice, and future research plans.

Dr Richard Conway (Dublin, Ireland) and Dr Elena Nikiphorou (London, UK) interview Dr Carlos Fernández-Díaz (Santander, Spain) about his recent paper, which examines the efficacy of abatacept in interstitial lung disease associated with rheumatoid arthritis. Their discussion includes the study’s key learning points, how this research may influence clinical practice, and future research plans.

Dr Marwan Bukhari asks Dr William Tillett (Bath, UK) and Dr Laura Coates (Oxford, UK) about the upcoming BSR psoriatic arthritis guideline. They explain why a new guideline is needed, how it will differ from others, and also offer some insight into the scope, which will consider PsA domains, comorbidities, therapy selection, and treatment strategies.

Dr Marwan Bukhari asks Dr William Tillett (Bath, UK) and Dr Laura Coates (Oxford, UK) about the upcoming BSR psoriatic arthritis guideline. They explain why a new guideline is needed, how it will differ from others, and also offer some insight into the scope, which will consider PsA domains, comorbidities, therapy selection, and treatment strategies.

Dr Marwan Bukhari asks Dr William Tillett (Bath, UK) and Dr Laura Coates (Oxford, UK) about the upcoming BSR psoriatic arthritis guideline. They explain why a new guideline is needed, how it will differ from others, and also offer some insight into the scope, which will consider PsA domains, comorbidities, therapy selection, and treatment strategies.

Dr Marwan Bukhari asks Dr William Tillett (Bath, UK) and Dr Laura Coates (Oxford, UK) about the upcoming BSR psoriatic arthritis guideline. They explain why a new guideline is needed, how it will differ from others, and also offer some insight into the scope, which will consider PsA domains, comorbidities, therapy selection, and treatment strategies.

Dr Mrinalini Dey asks Dr Deva Situnayake (Birmingham, UK) about his recent paper, in which a primary care database was used to examine epidemiology, morbidity and mortality in Behçet’s disease in the UK. Dr Situnayake identifies the study’s key findings, including the increasing prevalence of Behçet’s, as well as recommendations for clinical practice.

Dr Mrinalini Dey asks Dr Deva Situnayake (Birmingham, UK) about his recent paper, in which a primary care database was used to examine epidemiology, morbidity and mortality in Behçet’s disease in the UK. Dr Situnayake identifies the study’s key findings, including the increasing prevalence of Behçet’s, as well as recommendations for clinical practice.